The condition being studied is type 2 diabetes mellitus, a disease where the body cannot keep blood sugar at normal levels. The trial tests an experimental pill called elecoglipron taken alone, a known medicine dapagliflozin (brand name Forxiga) taken alone, and the two together, while some participants receive a placebo tablet that looks the same but contains no active drug. The purpose of the study is to find out whether the combination of elecoglipron and dapagliflozin improves blood‑sugar control better than dapagliflozin alone.
Participants will take a daily film‑coated tablet for about 40 weeks and will attend regular clinic visits where blood samples are taken to measure HbA1c (a test that shows average blood sugar over the past few months), Fasting plasma glucose (blood sugar after not eating), and will record their own readings using self‑monitoring of blood glucose. Weight, systolic and diastolic blood pressure will also be checked. The study follows a double‑blind design, meaning neither the participants nor the researchers know which pill is being taken until the study ends.
Czechia 
Denmark 
Germany 
Greece 
Slovakia 
